In particular, MEK1/2, BRAF, and TRK inhibitors have demonstrated significant promise in pediatric gliomas and extracranial solid tumors harboring these alterations and warrant further investigation in larger trials, as well as clinical consideration when these alterations are present. The gene discussed is MAP2K1; the disease is central nervous system cancer.